Target Name: MIR939
NCBI ID: G100126351
Review Report on MIR939 Target / Biomarker Content of Review Report on MIR939 Target / Biomarker
Other Name(s): microRNA 939 | hsa-miR-939-5p | mir-939 | hsa-mir-939 | MIRN939 | hsa-miR-939-3p | MicroRNA 939

MIR939: A Potential Drug Target or Biomarker

In the field of medical research, finding novel drug targets or biomarkers is crucial for the development of new therapeutic strategies and personalized medicine. One such promising candidate is MIR939, a microRNA molecule that has been implicated in various diseases and has the potential to serve as a therapeutic target or biomarker. This article delves into the characteristics and significance of MIR939, highlighting its potential applications in modern medicine.

What is MIR939?

MicroRNAs (miRNAs) are small non-coding RNA molecules that play a crucial role in regulating gene expression. They achieve this by binding to specific messenger RNAs (mRNAs) and causing their degradation or inhibiting their translation. MIR939 is a specific miRNA that has garnered attention due to its involvement in disease processes.

The Role of MIR939 in Diseases

MIR939 has been implicated in several diseases, including cancers, cardiovascular disorders, neurodegenerative diseases, and inflammatory conditions. Its dysregulation often leads to altered gene expression patterns that contribute to the pathogenesis of these diseases.

In cancers, MIR939 has been reported to be either upregulated or downregulated, depending on the type of cancer. For example, in breast cancer, MIR939 is downregulated, and its suppression leads to increased cancer cell proliferation and invasion. On the other hand, in hepatocellular carcinoma, MIR939 is upregulated and promotes cancer cell growth and metastasis. These observations suggest that the role of MIR939 in cancer is highly context-dependent.

Cardiovascular diseases, such as atherosclerosis and heart failure, are also influenced by MIR939. Studies have shown that the upregulation of MIR939 in vascular endothelial cells contributes to the development of atherosclerosis by stimulating inflammation and impairing normal endothelial functions. Additionally, MIR939 has been shown to play a role in cardiac remodeling following heart failure, highlighting its potential as a therapeutic target in cardiovascular diseases.

Neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, involve the abnormal accumulation of misfolded proteins in the brain. Recent studies have shown that MIR939 is significantly dysregulated in these conditions, suggesting its involvement in the progression of these diseases. Further research is required to understand the underlying mechanisms and exploit the therapeutic potential of targeting MIR939 in these complex diseases.

Inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease, also exhibit altered expression of MIR939. This miRNA has been shown to modulate immune responses and inflammatory processes, highlighting its potential as a biomarker for disease diagnosis, prognosis, and treatment response.

MIR939 as a Potential Therapeutic Target

The dysregulation of MIR939 in various diseases presents an opportunity for targeted therapeutic interventions. The development of specific molecules that can inhibit or mimic MIR939 function could potentially restore normal gene expression patterns and alleviate disease symptoms.

Several strategies have been explored to target MIR939 for therapeutic purposes. One approach involves the use of antisense oligonucleotides (ASOs) to specifically block MIR939 activity. ASOs are short DNA or RNA molecules that bind to the microRNA molecule and prevent it from interacting with its target mRNA. This approach has shown promising results in preclinical studies for certain cancers, providing a proof-of-concept for the therapeutic potential of targeting MIR939.

Another strategy involves the use of small molecules that can modulate MIR939 expression. High-throughput screening approaches have identified small molecules that can selectively upregulate or downregulate MIR939 expression. These molecules could potentially be developed into drugs for the treatment of diseases where MIR939 dysregulation is implicated.

MIR939 as a Biomarker

In addition to its potential as a therapeutic target, MIR939 also holds promise as a biomarker for disease diagnosis, prognosis, and treatment response. The altered expression of MIR939 in various diseases suggests its potential as a useful diagnostic tool. Furthermore, monitoring changes in MIR939 expression levels can provide insights into disease progression and treatment efficacy, aiding in personalized medicine approaches.

Studies have shown that the levels of circulating MIR939 in bodily fluids, such as blood and urine, correlate with disease status in several conditions. This suggests that MIR939 has the potential to be developed as a non-invasive biomarker for diseases, allowing for early detection and real-time monitoring of disease progression.


MIR939, a miRNA molecule, has emerged as a significant player in various diseases. Its dysregulation has been implicated in cancers, cardiovascular disorders, neurodegenerative diseases, and inflammatory conditions. With further research and development, targeting MIR939 holds promise as a therapeutic intervention strategy, while its altered expression could serve as a valuable biomarker for disease diagnosis and monitoring. As our understanding of MIR939 deepens, its potential as a drug target or biomarker in modern medicine will undoubtedly continue to captivate researchers and medical professionals alike.

Protein Name: MicroRNA 939

The "MIR939 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR939 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC